#USA #Irvine #PeproMene Bio #PMB-CT01 #BAFFR-CAR T

PeproMene Bio Showcases PMB-CT01 Data at 67th ASH Annual Meeting

PeproMene Bio, Inc., a biotechnology firm in clinical development, has made significant strides in treating relapsed and refractory B-cell malignancies with their innovative therapy, PMB-CT01 (BAFFR-CAR T). The company recently announced that two abstracts from ongoing Phase 1 trials of this groundbreaking treatment have been accepted for oral presentations during the 67th Annual Meeting of the American Society of Hematology (ASH) in 2025.

The Promising Therapeutic Landscape

PeproMene Bio is devoted to revolutionizing treatment options for patients suffering from heavily pretreated relapsed and refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and Non-Hodgkin Lymphoma (B-NHL). Analysts are eager to learn how PMB-CT01 can address critical unmet needs in these patient populations, particularly for those who have not had success with previous therapies primarily targeting the CD19 antigen.

Efficacy Insights

The upcoming presentations will highlight preliminary findings that demonstrate the safety and efficacy of PMB-CT01. Results from the Phase 1 dose-escalation studies (NCT04690595, NCT05370430) show promising outcomes:

• - For B-NHL Patients: All of the first seven patients treated reached a Complete Response (CR) within 1-3 months post-infusion, even among those who had previously undergone CD19-directed therapies and exhibited CD19-negative disease. Notably, these durable remissions have persisted for over 32 months in some cases (with a median duration of 17 months). No Grade >1 Cytokine Release Syndrome (CRS) or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) was reported, indicating a favorable safety profile for this treatment.
• - For B-ALL Patients: Among the six enrolled patients, four achieved an undetectable level of Minimal Residual Disease (MRD-) CR, with three of these patients being CD19-negative at enrollment. Each of these three individuals successfully transitioned to allogeneic hematopoietic cell transplantation, aimed at curative intent. Additionally, no Dose-Limiting Toxicities (DLTs) were observed, and Grade 2 CRS was reported in only one case.

Shedding Light on BAFF-R

The BAFF-R target, primarily expressed on B cells, is crucial for B-cell survival and significantly reduces the risk of antigen-loss escape, an often-seen challenge in treatments targeting CD19. As such, PMB-CT01 stands out as a pioneering therapy potentially capable of meeting the unique needs of these high-risk patient groups.

What’s Next? Key Presentations at ASH 2025

The following abstracts focused on PMB-CT01 will be presented:
1. Title: ‘BAFFR-CAR T cells demonstrate durable responses and manageable toxicities in r/r B-cell lymphomas’
Presenter: Elizabeth Budde, M.D., Ph.D.
Date & Time: December 6, 2025, at 2:45 PM
Abstract ID: abs25-7079

2. Title: ‘BAFFR-CAR T cells show promising safety and anti-leukemia efficacy in r/r B-cell ALL patients’
Presenter: Ibrahim Aldoss, M.D.
Date & Time: December 8, 2025, at 11:00 AM
Abstract ID: abs25-2035

These session highlights are anticipated to draw considerable attention within the hematology community and beyond, reaffirming PeproMene Bio's commitment to improving treatment outcomes for patients battling B-cell malignancies.

Conclusion

The data surrounding PMB-CT01 reinforces the perception of BAFF-R as a promising target in hematology that could lead to substantial improvements in therapeutic strategies for challenging cancers. With the ASH 2025 presentations on the horizon, stakeholders are encouraged to stay tuned for what might represent a new chapter in CAR T therapy for B-cell-related malignancies.

For media inquiries or detailed information about the clinical trials, please reach out to Hazel Cheng, Ph.D. at PeproMene Bio.